From: ETV2/ER71, the key factor leading the paths to vascular regeneration and angiogenic reprogramming
Animal model | Animal species | Delivery methods | Administration route and dose | Observation time points | Outcome | References |
---|---|---|---|---|---|---|
Hindlimb ischemia | Athymic nude mice | Lentivirus | Single IM injection of 25 µl (IFU 3 × 107/ml) into the adductor muscle (4 sites, a total 100 µl per animal) | Day 7, 21, 28 | Improved blood perfusion | Ref. [58] |
Myocardial infarct | C57/BL6 | Lentivirus | Single intra-myocardial injection of 5.6 × 106 IFU per site, a total two sites | 8 weeks after MI | Improved cardiac function Increased capillary density | Ref. [59] |
Myocardial infarct | Fisher 344 rats | Adeno-associated virus | Single intra-myocardial injection of 1 × 1012 GC per site, two sites | 8 weeks after MI | Improved cardiac function Less fibrosis | Ref. [59] |
Stroke | C57/BL6 | Nanochannel electroporation of plasmid DNA encoding EFF (Etv2, Foxc2, Fli1) into MEFs | Single intracranial (subarachnoid space) injection of EFF-transfected MEFs at day 7 of MCAO | Day 21 after MCAO | Enhanced cerebral vascularity, infarct resolution and motor activity | Ref. [112] |
Syngenic tumor model | C57/BL6 | ETV2 siRNA nanoparticle | Repeated IV injection of 1 nmol per mouse at day 9–17 after SC transplantation of LLC, a total 5 times, EOD | Day 19 after LLC transplantation | Reduction in tumor size, less vessels | Ref. [61] |
Heterotopic human GBM tumor | NOD/SCID mice | Lentiviral delivery of ETV2-specific gRNA/Cas9 into GBM cells | SC transplantation of ETV2-disrupted GBM cells (5 × 106 per mouse) | 2 months after GBM transplantation | Reduction in tumor size and hCD31+/KI67+ TDECs | Ref. [62] |